Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHIPPI-1808 HIPEC in Ovarian Cancer (PDS vs IDS)
2024-514706-31-01Phase 3Authorised
- Sponsor
- Centre Oscar Lambret
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised trial of cisplatin in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Centre Oscar Lambret. Primary endpoint: Disease-free survival. Planned start Nov 2024; status: authorised.
02
Drugs
cisplatin
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2024-514706-31-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514706-31-01.